icon-folder.gif   Conference Reports for NATAP  
 
  14th European AiDS Conference
Oct 16-19 2013
Brussels, Belgium
Back grey_arrow_rt.gif
 
 
 
Retrospective Comparison of Etravirine and Darunavir/Ritonavir as Dual Therapy in Early Treatment-Experienced Subjects (INROADS) to a Matched Historical Control Cohort
 
 
  Reported by Jules Levin
EACS - 14th European AIDSConference Oct 16-19 2013 Brussels, Belgium
 
Pedro Cahn on behalf of the GARDEL study group

EACS1.gif

EXTENSION
305 entered the extension Phase of the study,
66 declined
Most frequent reasons :
Most frequent reasons :
· Study not approved in Peru (22 )
· Virological failure at week 48 ( 14 ) ( failures at week 48 are 15 but one patient by mistake entered to extension phase and was approved to continue due to <50 copies at next visit )
· Patient decision ( 7 )
· Medical decision ( 6 )

EACS2.gif

EACS3.gif

EACS4.gif

EACS5.gif

EACS6.gif

EACS7.gif

EACS8.gif

One of the secondary endpoints is shown here. VL below 400 copies at week 24. As you can see, no significant difference was found, and this results were confirmed at week 48.-
· VIROLOGICAL FAILURES AT WEEK 24
7 virological failures have been reported at week 24 ,
( 1 in DT and 6 in TT )
NO NEW MUTATIONS ( 5 amplified, 1 not done , 1 didnīt amplify )

EACS9.gif

EACS10.gif

EACS12.gif

EACS13.gif